Geoffrey Porges
Stock Analyst at SVB Leerink
(1.34)
# 3,541
Out of 4,974 analysts
122
Total ratings
42.86%
Success rate
-6.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $24.88 | +125.08% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $12.19 | +720.34% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $573.38 | +48.24% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $74.93 | -35.94% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $283.64 | -23.85% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $212.56 | -36.49% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $12.92 | -14.86% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $115.05 | -34.81% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $46.50 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $13.93 | -28.21% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $12.11 | +6,093.23% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $396.12 | -55.82% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $23.82 | +252.72% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $40.50 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $8.29 | +635.83% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $140.67 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $24.88
Upside: +125.08%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $12.19
Upside: +720.34%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $573.38
Upside: +48.24%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $74.93
Upside: -35.94%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $283.64
Upside: -23.85%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $212.56
Upside: -36.49%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $12.92
Upside: -14.86%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $115.05
Upside: -34.81%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $46.50
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $13.93
Upside: -28.21%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $12.11
Upside: +6,093.23%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $396.12
Upside: -55.82%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $23.82
Upside: +252.72%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $40.50
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $8.29
Upside: +635.83%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $140.67
Upside: -